Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children (ESPHALL)
This study is currently recruiting participants.
Study NCT00287105   Information provided by Rennes University Hospital
First Received: February 3, 2006   Last Updated: August 19, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Lymphoblastic Leukemia
Philadelphia Chromosome
Additional conditions recognized in this trial
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Chromosome Aberrations
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Translocation, Genetic
Interventions listed in this trial
Standard chemotherapy + Imatinib
Standard chemotherapy
Additional drug interventions recognized in this trial
Imatinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Rennes University Hospital
Ministry of Health, France
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services